| INTRODUC TI ON
Amyotrophic lateral sclerosis (ALS) is a rare and unfortunately relentlessly progressive and terminal neurodegenerative disease characterised by the selective degeneration of motor neurons within the motor cortex, brainstem and spinal cord. In the USA, approximately 14 cases of ALS are diagnosed each day, and 30 000 people are living with the disease. [1] [2] [3] The incidence of ALS in populations of European descent is approximately 2 per 100 000 per year, and the lifetime risk of developing ALS for individuals 18 years of age or older has been estimated to be 1 in 420 for women and 1 in 350 for men, with the white-to-non-white ratio of 1.6:1. 4 Clinically, ALS is classified as either sporadic (90% of the cases) or familial (10% of the cases).
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ALS is diagnosed when progressive symptoms consistent with upper and lower motor neuron dysfunction present in one of four body segments (cranial/bulbar, cervical, thoracic or lumbosacral), then spread to other segments over a period of months to years. 6 The course is insidiously progressive, with associated involuntary weight loss and muscle wasting unrelated to nutrition. ALS is both a clinical diagnosis and one with sensory and motor nerve conduction studies and electromyography, which are standard parts of the evaluation.
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The progressive nature of ALS requires robust prognostic and diagnostic tools that can enhance early clinical prediction and improve the timing of appropriate management. With differing rates of motor neuron degeneration, clinical disease manifestations may vary widely among patients, resulting in several clinical phenotypes. 7, 8 In addition, since ALS usually results in death due to respiratory muscle weakness, pulmonary function tests (PFTs) have frequently been utilised as predictors of individual survival. 9 Sitting forced vital capacity (FVC), the best studied of pulmonary tests, correlates with survival in ALS, 10,11 but may not be the best available PFT for the prediction of death or respiratory failure. 12 Supine FVC and maximal inspiratory pressures (MIP) are more sensitive than sitting FVC for the detection of respiratory muscle weakness. 13 The American Academy of Neurology supports the utility of supine (rather than sitting) FVC MIPs as more sensitive tests for the detection of respiratory muscle weakness. 12, 13 However, there is a large degree of interpatient variability in the rate of ALS progression, with some patients dying or requiring respiratory support within months and others having relatively prolonged survival. 14 The consequences of such uncertainty in survival result in coping and planning difficulties for patients and their families while presenting obstacles to research on ALS, as it may be difficult to assemble a cohort of patients that can be expected to complete a clinical trial.
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Several studies explored the variation in PFTs on predicting survival of ALS patient. [15] [16] [17] [18] However, only a few have assessed the progression rate of such characteristics based on ALS clinical phenotypes. 1 Hence, further information based on the entire course of the disease is needed.
The primary goal of our single-centre study was to evaluate the utility of PFTs in predicting ALS outcomes that may potentially impact the timing of the initiation of non-invasive positive pressure ventilation (NIPPV) or placement of tracheostomy, based on welldefined ALS clinical phenotypes.
| MATERIAL S AND ME THODS

| Study population
All participants were veterans, 18 years of age or older, who fulfilled El
Escorial criteria 6 for "definite" or "probable" ALS. They presented clinically with upper and lower motor neuron dysfunction in three or two body (bulbar or spinal) regions. 6 ALS patients who met either of these criteria were managed similarly. All study participants underwent sitting and supine spirometry at a tertiary-care academic medical centre for veterans in the USA from 1 January 2010 to 31 December 2014.
Patients excluded from analysis had a family history of ALS, prior history of symptomatic obstructive or restrictive chronic pulmonary disease unrelated to ALS, fatal diagnosis precluding survival for 6 months, cognitive disorders, uncontrolled heart failure or a medical history of monoclonal gammopathies.
The study protocol was approved by the University of South Florida Institutional Review Board and the James A. Haley Veterans'
Hospital Research and Development Committee.
| Pulmonary function testing
All PFTs were performed at our facility's pulmonary function laboratory, which meets applicable American Thoracic Society standards.
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We utilised the tests in predicting patients' outcomes at 6 months Age in years at diagnosis (mean±SD) Clinically, relevant cut-off points were used for supine and sitting FVC, that is, severe (<50% predicted FVC), moderate (50%-64%), mild (65%-79%) and no (>80%) restriction. 13, 16, 20 Also, maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were determined with "normal" cut-off points ranging from <−70 cm H 2 O to >70 cm H 2 O, respectively.
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The rate of change (RoC) for both sitting and supine FVC was calculated from the slope of the line derived from the measured FVC (% predicted) values on each measurement.
| Outcome measurements
The study's primary outcome measure was tracheostomy-free sur- 
| Independent variables
Non-pulmonary characteristics assessed at the time of pulmonary function testing by neurology and pulmonary services included demographic data, onset of ALS symptoms and time from symptom onset to initial and subsequent spirometry testing. Also, weight and height at the time of ALS diagnosis were noted, and body mass index was calculated.
The clinical area of disease onset was designated as global 
| Statistical analyses
Descriptive statistics analyses were performed utilising means and standard deviations (SD), medians and interquartile ranges (IQR) and frequencies wherever appropriate. Also, continuous variables were compared using t tests, and baseline categorical variables were compared using chi-square tests.
Survival was calculated from the time of the patients' ALS onset.
Bivariate, non-parametric survival analyses using the primary endpoint of tracheostomy-free survival or death were carried out using the methods of Kaplan and Meier. Statistical significance was tested using Wilcoxon tests.
To adjust for other possible confounding factors that might be associated with survival, Cox proportional hazard modelling was used. The Cox proportional hazards model is a regression model frequently used in medical research for investigating the association between the survival time of patients and one or more variables.
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The latter was used for the multivariate regression analysis of each pulmonary predictor with age, clinical phenotype onset, time from symptom onset to diagnosis, other non-pulmonary comorbidities and initiating NIPPV. Continuous variables were categorised into clinically appropriate groups.
| RE SULTS
| Participant characteristics
Data analyses were conducted for a total of 137 ALS patients (134 men and 3 women; Table 1 ). Mean age at the time of diagnosis of was 62.31 (±11.37) years old. Utilising the El Escorial criteria, diagnosis of ALS was definite or probable in 75% and 25% of subjects, respectively.
| ALS clinical phenotypes
The clinical area of disease onset for the majority of patients (n = 122) was designated as global phenotype, then subgrouped according to their region of onset as bulbar (n = 29), cervical (n = 45), or lumbar (n = 48). Twelve patients had a flail phenotype with the region of onset as either arms (n = 5) or legs (n = 7). Also, three patients had PLS. The median (IQR) ALSFRS-R score on presentation was 29.00 (22.00 to 34.00), with a percentage of weight loss of 4.00% (±9.90) from prediagnosis weight in all clinical phenotypes, except PLS, where no weight loss was noted.
| PFT results
All of the 137 patients underwent PFTs during the study period, av- (Table 2) . Also, the average MIP and MEP on presentation were −59.94 (±34.45) and 58.17 (±31.11) cm H 2 O, respectively. All spirometry results on presentation were higher for both FA and FL clinical phenotypes (Table 2) .
| Rate of change
On further analysis, a total of 89 patients underwent PFTs at least twice during the study period, with an average of four times, and the average time between tests was 3.95 (±3.92) months (Table 3) 
| Survival
Based on previously published reports, there is variability in the average RoC in the sitting FVC of various ALS cohorts. 24, 25 In such reports, the mean RoC of the cohort was used as the cut-off point for the cohort's survival analysis. ALS patients were grouped into those with RoC that were either greater or less than the average for the group. 24, 25 We used another approach for the analysis of the effect of RoC, based on our observation that the RoC is different among the same ALS cohort's phenotypes.
We determined a general cohort mean RoC of −1.19 (±2.38)/−1.07 (±3.78) % per month [P = 0.5] of the sitting/supine FVC, respectively.
However, median monthly RoC was different among the ALS phenotypes (Table 3) , with higher variation among the global ALS phenotypes. In addition, we compared the changes in sitting and supine FVC % predicted among those with global ALS phenotypes who were able to use AVAPS for at least 8 hours/day (n = 18; Table 4 ). 
Leg (n = 7)
Months from diagnosis to first PFT (Table 1) .
| D ISCUSS I ON
In our study, serial measurements of sitting and supine FVC in ALS patients were significantly associated with disease progression and the need for NIPPV and tracheostomy placement. These findings were significant even after controlling for patients' non-pulmonary comorbidities. Although all the spirometry results were higher on the presentation for both FA and FL clinical phenotypes ( of patients with a higher initial rate of decline (log-rank P < 0.0001).
Hence, although the initial rate of FVC % decline can be predictive of survival of ALS patients, more frequent measurement of FVC and other PFT indices in such patient populations can be quite beneficial in predicting tracheostomy-free survival or the need for various respiratory support.
Furthermore, based on previously published reports, there is variability in the average RoC in the sitting FVC of various ALS cohorts. 24, 25 In such reports, the mean RoC of the cohort was used as the cut-off point for the cohort's survival analysis. ALS patients were grouped into those with rates of change that were either greater or less than the average for the group. 24, 25 We used another approach for the analysis of the effect of RoC based on our observation that the rate of change is different among the same ALS cohort's phenotypes.
Although 21% (n = 29) of our cohort underwent tracheostomy placement, only 17 of them were performed at our institution. The other 12 participants were transferred to our facility after undergoing emergency tracheostomy elsewhere. Not knowing the conditions under which this decision was made may be a limitation, since the medical determinants preceding the tracheostomy are unknown.
Our ALS management approach focused on early initiation of NIPPV, based on the decline in RoC rather than absolute values of either sitting or supine FVC. As a result, AVAPS support was initiated at an average sitting FVC of 65% of predicted and the corresponding supine FVC of 50% (Figure 3 ). It appears that the initiation of AVAPS, based on the RoC of either sitting or supine FVC, may have the potential to increase survival rate and slow down the RoC, as indicated in our survival analysis of the 18 patients with global ALS phenotypes who were able to use AVAPS for at least 8 hours/day (Figure 2 ). Further research is needed across multiple sites to be able to have higher numbers in each phenotype and more women represented to demonstrate the potentially increased survival rate when the AVAPS is introduced sooner in the disease process. In addition, further exploration of how phenotypes interact with genetics to affect the RoC may yield even more productive research outcomes that can be translated into treatment processes.
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Our study has limitations in that we did not evaluate hypoventilation and survival in ALS patients by the sniff nasal inspiratory force (SNIF) for any of the ALS subjects as it was not available in our PFTs laboratory. 27 Also, although our bivariate analysis revealed that gender was not associated with specific ALS survival, this finding has to take into consideration that only three women were included in our study due to the relatively higher number of males in our study population of veterans.
However, the strength of our study relates to our ability to include a large number of ALS patients from a single institution, which provided uniformity in the various evaluation and testing methodologies. Also, compared to similar studies with fewer subjects, we were able to place our patients into distinct ALS clinical phenotypes, rather than grouping them as bulbar and other types. 28 In addition, compared to other research where fewer serial studies were performed than planned, 15, 28 we were able to include 89 ALS subjects with various clinical phenotypes in our serial PFT analysis. This allowed us to analyse a larger dataset and calculate RoC for the different ALS clinical phenotypes.
| CON CLUS IONS
In summary, our results support previous studies that demonstrated the utility of FVC (% predicted) rate of change as an independent predictor of survival in ALS. 25 Also, our study emphasised the im- 
D I SCLOS U R E S
The authors declare that they have no conflict of interest. 
AUTH O R CO NTR I B UTI O N S
